MYOV - Is Myovant's New Prostate Cancer Drug a Game Changer?
A number of biotech stocks have made major moves over the past week. One of those was Myovant Sciences (NYSE: MYOV), a $1.1 billion biopharma company, which had its shares more than double on Nov. 19 following impressive clinical trial results in treating early, androgen-sensitive prostate cancer.
With hundreds of thousands of new prostate cancer patients diagnosed in the U.S. alone, there's plenty of potential for Myovant to hit a financial home run if its drug receives U.S. Food and Drug Administration approval. At the same time, this drug is well-positioned to become a leading treatment option for women with uterine fibroids.
Let's take a more detailed look at the company's recent results and the strength of its flagship drug candidate.